Welcome

Sign out Have a question? We're here to help

Copyright © 2020 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Collegium Pharma (COLL)

$23.41 0.51 (2.13%)

17:57 EST COLL Stock Quote Delayed 15 Minutes

Volume:

Previous Close $23.41

Market Cap 773.56M

PE Ratio -10.40

EPS -2.25

Volume (Avg. Vol.) 232,100

Day's Range 23.39 - 24.40

52-Week Range 10.01 - 24.72

Dividend & Yield N/A (N/A)

COLL Stock Predictions, Articles, and Collegium Pharma News

From the Web

The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares

From Benzinga Jan 17, 2020

The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 16.) Acceleron Pharma...

Stocks That Hit 52-Week Highs On Thursday

From Benzinga Jan 16, 2020

During Thursday's morning session, 405 companies made new 52-week highs. Significant Points: MACOM Technology (NASDAQ: MTSI) was the largest firm on a market cap...

The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics

From Benzinga Jan 16, 2020

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 15) 10X Genomics Inc (NASDAQ...

Stocks That Hit 52-Week Highs On Wednesday

From Benzinga Jan 15, 2020

On Wednesday, 277 companies set new 52-week highs. Noteworthy Points: NextEra Energy (NYSE: NEE) was the largest company by market cap to set a new 52-week high this...

Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?

From Zacks Investment Research Jan 14, 2020

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug

From Benzinga Jan 14, 2020

The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 13.) Arvinas Inc (...

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy